Guido Oelkers, Sobi CEO

September 3, 2021 09:11 AM EDTUpdated 10:59 AM

Private equity, sovereign wealth fund ally on an $8B buyout aimed at taking rare disease player private

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Trump administration reveals 'most favored nation' drug price country targets

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Why Regeneron is buying 23andMe

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?